← Back to Search

Monoclonal Antibodies

Secukinumab for Nail Psoriasis

Phase 4
Recruiting
Led By Alexis Ogdie-Beatty, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist
Age 18-85
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 24 weeks
Awards & highlights

Study Summary

This trial will study the effectiveness of secukinumab, an FDA-approved drug, in treating nail psoriasis.

Who is the study for?
This trial is for adults aged 18-85 with active skin psoriasis or a history of it, and significant nail psoriasis. It's not open to those with fungal nail infections, inflammatory bowel disease, metal implants affecting MRI use, current infections, or past IL-17 inhibitor treatments.Check my eligibility
What is being tested?
The study tests Secukinumab (an FDA-approved psoriasis medication) specifically on nail psoriasis. Participants will self-administer the drug using an auto-injector and researchers will monitor how quickly and effectively the treatment works.See study design
What are the potential side effects?
Secukinumab may cause side effects like cold symptoms, diarrhea, upper respiratory infections, hives at injection site. Since it affects the immune system, there might be an increased risk of other infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have or had skin psoriasis diagnosed by a dermatologist.
Select...
I am between 18 and 85 years old.
Select...
I have psoriasis affecting 4 or more of my fingernails.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
NAPSI
Secondary outcome measures
DLQI
PASI
Physician Global Assessment of Nail Disease

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open LabelExperimental Treatment1 Intervention
Secukinumab

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,880,048 Total Patients Enrolled
11 Trials studying Psoriasis
2,758 Patients Enrolled for Psoriasis
NovartisIndustry Sponsor
1,610 Previous Clinical Trials
2,719,230 Total Patients Enrolled
8 Trials studying Psoriasis
4,018 Patients Enrolled for Psoriasis
Alexis Ogdie-Beatty, MDPrincipal InvestigatorUniversity of Pennsylvania
3 Previous Clinical Trials
487 Total Patients Enrolled
1 Trials studying Psoriasis
100 Patients Enrolled for Psoriasis

Media Library

Secukinumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04535999 — Phase 4
Psoriasis Research Study Groups: Open Label
Psoriasis Clinical Trial 2023: Secukinumab Highlights & Side Effects. Trial Name: NCT04535999 — Phase 4
Secukinumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04535999 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please explain what Secukinumab Auto-Injector is typically prescribed for?

"Secukinumab Auto-Injector is typically administered to treat ankylosing spondylitis. However, it has also been found to be beneficial for patients suffering from psoriatic arthritis, enthesitis related arthritis (ERA), and debilitating plaque psoriasis."

Answered by AI

Who meets the criteria for participating in this research initiative?

"This trial seeks 40 participants with psoriasis aged 18-85. To qualify, one must have active psoriatic nail disease (minimum of 4 fingernails or a NAPSI score over 20) and either current skin psoriasis without minimum PASI/BSA criteria or documented past skin psoriasis by a dermatologist."

Answered by AI

Has Secukinumab Auto-Injector been subject to any prior analyses?

"Currently, 27 research trials are being conducted for Secukinumab Auto-Injector; 13 of those studies have reached Phase 3. While the majority take place in Brest and Buenos Aires, there is a total of 1040 sites running investigations on this treatment."

Answered by AI

How many individuals are contibuting to this clinical experiment?

"Currently, this clinical trial has finished recruiting participants. The study was first posted on February 7th 2022 and the information was most recently updated on February 11th 2022. If you are pursuing other studies, 167 trials involving psoriasis patients and 27 trials regarding Secukinumab Auto-Injectors are actively looking for candidates right now."

Answered by AI

Is there still capacity for participants in this medical experiment?

"Per the clinicaltrials.gov database, this medical study is no longer recruiting individuals for participation; it was first posted on February 7th 2022 and last modified on February 11th 2022. However, 194 other trials are still actively enrolling patients at present."

Answered by AI

Has Secukinumab Auto-Injector been given regulatory approval by the FDA?

"Secukinumab Auto-Injector has been approved for clinical use, resulting in its safety index of 3."

Answered by AI

Is the age criterion of 55 years or older necessary to qualify for this clinical experiment?

"According to the trial's eligibility conditions, prospective participants must be at least 18 years old and no older than 85."

Answered by AI
~17 spots leftby Dec 2025